Pediatric Clinics of North America - CIPERJ

376 RODRIGUEZ & HOOTS
[42] Carcao M, St. Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors:
a Canadian experience. Haemophilia 2006;12:7–18.
[43] Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high
titre inhibitors. Haemophilia 2006;12:218–22.
[44] Lawn RM. The molecular genetics of hemophilia: blood clotting factors VIII and IX. Cell
1985;42:405–6.
[45] Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships
and inhibitor development. Semin Thromb Hemost 2003;29(1):23–30.
[46] Pierce GF, Lillicrap D, Pipe SW, et al. Gene therapy, bioengineered clotting factors and
novel technologies for hemophilia treatment. J Thromb Haemost 2007;5:901–6.
[47] Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006;13(5):301–7.
[48] Miao HZ, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for
improved secretion. Blood 2004;103:3412–9.
[49] Pipe SW. The promise and challenges of bioengineered recombinant clotting factors.
J Thromb Haemost 2005;3:1692–701.
[50] Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of
bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977;
252:3578–81.
[51] Molineaux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy
2003;23:3S–8S.
[52] Baru M, Carmel-Goren L, Barenholz Y, et al. Factor VIII efficient and specific non-covalent
binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic
efficacy. Thromb Haemost 2005;93:1061–8.
[53] Goyal P, Goyal K, Vijaya Kumar SG, et al. Liposomal drug delivery systemsdclinical
applications. Acta Pharm 2005;55:1–25.
[54] Spira J, Ply Ushch OP, Andreeva TA, et al. Prolonged bleeding-free period following
prophylactic infusion of recombinant factor VIII (Kogenate (R) FS) reconstituted with
pegylated liposomes. Blood 2006;108:3668–73.